FDA outlines benefits and risks of emerging augmented and virtual reality medical devices – MedTech Dive

AR/VR are already changing healthcare. The FDA’s non-exhaustive list of medical devices that incorporate the technology features 39 products across therapeutic areas including orthopedics, ophthalmics, radiology, neurology and cardiovascular.   
Having reviewed and authorized “a growing number of devices” with AR/VR features, the FDA has now set out its thinking on the emerging class of products. The document provides definitions of AR and VR, and then digs into how the technology is impacting medical devices. The FDA sees value in the ability of AR/VR to move care to patients’ homes and other non-clinical settings.  
“This could enable patients, including the socioeconomically vulnerable and underserved communities, the elderly or disabled, to access needed health care services when accessing them in person would otherwise be difficult, and this could make it easier, and more likely, for patients to complete treatment and monitoring regimens,” the agency wrote.
The FDA sees potential to use the technology in areas including pediatric diagnostics and treatments, pain management and mental health. Device developers that deploy the technology could deliver a range of benefits, either to all patients with a condition or to subsets of individuals with specific needs. The FDA lists accelerated diagnosis and the mitigation of preoperative anxiety as potential benefits. 
As companies work to deliver those benefits, they will need to be alert to the potential risks of AR/VR. The FDA lists a handful of general probable risks, including cybersecurity and privacy threats, as well as specific concerns related to pediatric populations.
Get the free daily newsletter read by industry experts
Analysts at Rock Health said “the market isn’t the same as it was” after seeing a sharp drop in late-stage deals.
Type 1 diabetes patients who used a customizable, open-source artificial pancreas, an insulin pump and a Dexcom G6 CGM found it more effective at controlling blood glucose than conventional sensor-augmented insulin pumps.
Subscribe to MedTech Dive for top news, trends & analysis
Get the free daily newsletter read by industry experts
Want to share a company announcement with your peers?
Get started ➔
Analysts at Rock Health said “the market isn’t the same as it was” after seeing a sharp drop in late-stage deals.
Type 1 diabetes patients who used a customizable, open-source artificial pancreas, an insulin pump and a Dexcom G6 CGM found it more effective at controlling blood glucose than conventional sensor-augmented insulin pumps.
The free newsletter covering the top industry headlines

source